key: cord-0746442-ite4u8il authors: Chan, Kathryn; Sharif, Sameer; Rochwerg, Bram title: Is dexamethasone an effective treatment for severe COVID-19 patients: Journal Club review date: 2021-01-04 journal: Can J Emerg Med DOI: 10.1007/s43678-020-00033-3 sha: 25d7ecec74e560f6baea631c499ec528305d902b doc_id: 746442 cord_uid: ite4u8il nan Coronavirus disease 2019 (COVID-19) can cause a severe respiratory illness that may require critical care and ventilatory support. Therapeutic management continues to evolve as new evidence emerges. Remdesivir has shown clinical benefit in shortening time to recovery but its impact on mortality remains uncertain [1] . Corticosteroids may play a role in the management of severe COVID-19 as a hyperinflammatory state is thought to contribute to disease progression. To evaluate the effects of dexamethasone in patients hospitalized with COVID-19. Multi-centre, open-label, randomized controlled trial. Hospitalized patients across 176 sites in the United Kingdom with clinically suspected or laboratory-confirmed COVID-19 infection. Initially limited to adults > 18 but this age limit was removed in May 2020. Pregnant and breastfeeding patients were included. Exclusion criteria included any patients who, in the opinion of the attending clinician, might be placed at an increased risk if they were to participate in the trial. Dexamethasone 6 mg once daily, per os (PO) or intravenous (IV), for up to 10 days (or until hospital discharge, if sooner) plus usual standard of care. Usual standard of care. All-cause 28-day mortality. Length of hospital stay, post-randomization receipt and duration of invasive mechanical ventilation (including extracorporeal membrane oxygenation), receipt of hemodialysis or hemofiltration, cause-specific mortality, major cardiac arrhythmia. In total, 2104 patients were randomized to receive dexamethasone and 4321 received usual care (1:2 ratio • Unclear how patients were recruited and if this was done consecutively. • Exclusion criteria was vague and provider dependent. 15% of patients initially recruited were considered by the treating physician to not be suitable for randomization to dexamethasone. • Study design was open label so physicians, patients, and research staff were aware of the assigned treatments. This may have resulted in different management in patients who received the intervention (differential use of cointerventions), and may have increased the effect size of dexamethasone. • There was no placebo, with the control arm receiving usual care. Although a placebo arm is ideal the openlabel adaptive design facilitates rapid research generation during a pandemic. • 8% of patients randomized to usual care ultimately received dexamethasone; however, this would lead to an underestimation of the treatment effect of the glucocorticoid. • The duration of dexamethasone therapy was not standardized. • Overall, the absolute mortality difference of 2.8% did not meet the prespecified clinically relevant difference of 4% used in the statistical planning. A recent systematic review and network meta-analysis shows that corticosteroids are the only therapy that decreases mortality in COVID-19, while hydroxychloroquine, remdesivir, and lopinavir-ritonavir may reduce symptom duration [1] . Dexamethasone is recommended by the National Health Institute in the United States for COVID-19 patients who are mechanically ventilated or requiring oxygen [2] . Since May 2020, dexamethasone has been listed as a Tier 3 drug shortage in Canada [3] . In severe COVID-19 patients, dexamethasone 6 mg PO/ IV for up to 10 days showed an important reduction in mortality and should be now considered the standard of care. This effect was most pronounced in patients requiring invasive mechanical ventilation but was also present in all severe COVID-19 patients (defined as oxygen saturation < 94% on room air). Dexamethasone should not be used in COVID-19 patients who do not require oxygen, as there was no benefit demonstrated. Drug treatments for covid-19: living systematic review and network meta-analysis COVID-19 Treatment Guidelines Panel. Coronavirus disease 2019 (COVID-19) treatment guidelines. National Institute of Health Exceptional importation and sale of drugs in relation to COVID-19: tier 3 drug shortages: Government of Canada Conflict of interest None declared.